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A B S T R A C T
Preclinical data suggest that hypoxia stimulates fibroblast growth factor 23 (FGF23) transcription and cleavage
in osteocytes, resulting in elevated circulating c-terminal (cFGF23) levels but normal intact FGF23 (iFGF23)
levels. We conducted a case-control study within the Hispanic Community Health Study/Study of Latinos to
investigate whether sleep disordered breathing, as a model of hypoxemia, is independently associated with
elevated cFGF23 levels in the general population and with elevated cFGF23 and iFGF23 levels in patients with
chronic kidney disease (CKD), in whom FGF23 cleavage may be impaired. Cases (n=602) had severe sleep
disordered breathing defined as an apnea/hypopnea index (AHI) of ≥30. Controls without severe sleep dis-
ordered breathing (n= 602) were matched for sex and CKD stage. The median AHI in the cases was 45.8 (IQR
35.5–62.5) compared to 2.6 (IQR 0.6–8.2) in the controls. Cases had higher cFGF23 levels than controls
(66.2 RU/mL, IQR 52.8–98.4 vs. 61.2 RU/mL, IQR 49.5–80.1, p value<0.001). There were no differences in
iFGF23 levels between cases and controls. In adjusted linear regression and multinomial regression analyses,
body mass index attenuated the relationship between severe sleep disordered breathing and cFGF23 levels. No
significant relationships were seen in analyses of severe sleep disordered breathing and iFGF23 levels or in
analyses of iFGF23 and cFGF23 stratified by CKD status. Additional studies using other models of intermittent
and chronic hypoxia are needed to confirm whether hypoxia stimulates FGF23 transcription in humans and to
determine the impact on iFGF23 levels in CKD.
1. Introduction
Fibroblast growth factor 23 (FGF23) is an osteocyte-derived hor-
mone that regulates systemic phosphate and vitamin D homeostasis [1].
Chronic kidney disease (CKD) represents the most common setting of
secondary FGF23 excess. FGF23 levels rise early in CKD and FGF23
levels may be thousands-fold higher than in CKD by the time end stage
renal disease occurs [2]. Preclinical data demonstrate direct toxic ef-
fects of FGF23 on cardiac myocytes through activation of fibroblast
growth factor receptor 4 [3, 4]. Results from observational studies are
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monitor for overnight recording at their baseline clinic visit, when
participants also had their blood drawn [29]. This monitor measures
airflow via nasal cannula, pulse rate, snoring levels, and hemoglobin
oxygen saturation via transcutaneous oximetry [29]. All sleep records
were scored at a central sleep reading center by a certified poly-
somnologist, who manually edited artifacts, identified periods of sleep,
and interpreted the oxyhemoglobin desaturation associated with each
respiratory event [29]. Respiratory events were defined as a 50% or
greater reduction in airflow that lasted ≥10 s [29]. Apnea/hypopnea
index (AHI)≥ 30 was defined as> 30 respiratory events per estimated
sleep hour with 3% desaturation. Within and between scorer reliability
was high for the AHI (intra-class and inter-class correlation coeffi-
cients> 0.95) [29]. Severe sleep disordered breathing was defined as
AHI≥ 30 on overnight sleep testing.
2.3. Outcomes
Our primary outcomes were plasma cFGF23 and iFGF23 levels. We
measured FGF23 using Quidel's (formerly known as Immutopics)
cFGF23 and iFGF23 assays (San Clemente, California, Quidel) at the
HCHS/SOL Central Laboratory at the University of Minnesota after a
single thaw of frozen samples. To quantify precision, we measured in a
blinded manner a random selection of 10% of samples in duplicate. The
mean intra-assay coefficients of variation for cFGF23 and iFGF23 were
4.4% and 6.6%. The inter-assay coefficients of variation ranged from
4.8–8.3% for cFGF23 and 6.1–6.4% for iFGF23.
2.4. Covariates
Information on participant demographics, medication use and
clinical data was collected at the baseline visit [27, 28]. Resting blood
pressure was measured via standardized protocols. Diabetes was de-
fined as one of the following: fasting plasma glucose level≥ 126mg/
dL, a 2-hour post-load glucose level≥ 200mg/dL, hemoglobin A1C
level≥ 6.5%, or documented use of hypoglycemic agents on their
medication inventory [31, 32]. The centralized laboratory measured
serum creatinine and calcium, and urinary albumin-to-creatinine ratio
(UACR) via standard assays. Phosphate was measured in plasma on a
Roche Cobas 6000 Chemistry Analyzer (Roche Diagnostics Corpora-
tion) using a colormetric method. For plasma phosphate, the laboratory
intra-assay CV was 0.8% at a concentration of 6.1mg/dL and the inter-
assay CV was 1.9% at a concentration of 3.7 mg/dL. CKD was defined as
an estimated glomerular filtration rate (eGFR) < 60mL/min/1.73 m2
using the creatinine-based Chronic Kidney Disease Epidemiology Col-
laboration Cystatin C equation [33]. The amount of missing data for
covariates was minimal and less than< 0.5%.
2.5. Statistical analysis
We used standard descriptive statistics to summarize and compare
baseline characteristics of our study population according to presence
of severe sleep disordered breathing at study enrollment.
To test the association of sleep disordered breathing with FGF23
levels, we fit separate models for cFGF23 and iFGF23. First, we used
multinomial logistic regression analyses with cFGF23 and iFGF23 ex-
pressed in ascending quartiles, as previously done [7, 34]. We then
examined FGF23 as a continuous outcome variable in linear regression
models, for which we log transformed cFGF23 and iFGF23 levels be-
cause they were not normally distributed. We hierarchically adjusted
all models for potential confounding factors, including demographics
(age and sex), CKD risk factors (eGFR, albuminuria and plasma phos-
phate), comorbidities (blood pressure, smoking, diabetes, and coronary
heart disease), and inflammation (C-reactive protein [CRP]). In our
final model, we further adjusted for body mass index.
Given that FGF23 cleavage may be impaired in CKD [15, 26], we
performed pre-planned exploratory subgroup analyses in those with
corroborative: higher FGF23 levels are strongly associated with left 
ventricular hypertrophy, cardiovascular events and mortality in pa-
tients with CKD [5–12]. Collectively, these findings have spurred in-
vestigations to identify modifiable factors that regulate circulating 
FGF23 levels.
Studies in animal models demonstrate that the balance between 
FGF23 transcription and post-translational cleavage of newly synthe-
sized FGF23 protein determines levels of circulating bioactive FGF23 
[13]. FGF23 transcription is upregulated in response to known stimuli 
and in health, this is matched by an increase in post-translational 
FGF23 cleavage [13, 14]. Thus, circulating levels of biologically-active 
hormone, which are measured by intact assays (iFGF23), stay within 
the normal range, but C-terminal inactive fragments are elevated, 
which are measured by assays that detect both the biologically-active 
intact hormone and C-terminal fragments (cFGF23) [13–15]. Iron de-
ficiency and inflammation are two recently discovered stimuli of FGF23 
transcription that are accompanied by parallel increases in FGF23 
cleavage, resulting in elevations of cFGF23 but not iFGF23 levels. In 
CKD, FGF23 cleavage may be impaired such that stimuli that upregu-
late FGF23 transcription in osteocytes produce elevations in both 
cFGF23 and iFGF23 [1]. Preclinical data demonstrate that hypoxia may 
be a novel stimulus of FGF23 transcription [16]. However, few clinical 
studies have investigated the effect of hypoxemia on circulating FGF23 
levels in health and in CKD.
Sleep disordered breathing is a common cause of nocturnal hypox-
emia that is strongly associated with increased risk of cardiovascular 
disease in the general population and in patients with CKD [17–25]. We 
conducted a nested case-control study within a large prospective cohort 
of individuals with and without CKD to test the hypothesis that in-
dividuals with severe sleep disordered breathing would have higher 
baseline cFGF23 levels compared to individuals without severe sleep 
disordered breathing. Given that post-translational cleavage of FGF23 
may be impaired in CKD [15, 26], in exploratory analyses, we tested the 
hypothesis that individuals with sleep disordered breathing and CKD, 
defined as an estimated glomerular filtration rate < 60 mL/min/ 
1.73 m2, would have elevations in both cFGF23 and iFGF23 levels.
2. Methods
2.1. Study population and design
The Hispanic Community Health Study/Study of Latinos (HCHS/
SOL) is an ongoing multi-center prospective cohort study of risk factors 
for and the prevalence of cardiovascular, pulmonary and chronic dis-
eases in the Hispanic/Latino population [27, 28]. The HCHS/SOL study 
population included 16,415 participants aged 18–74 years who were 
recruited between 2008 and 2011 from four field centers across the 
United States: Chicago, IL; Bronx, NY, Miami, FL; San Diego, CA. The 
sampling design and implementation of the HCHS/SOL were previously 
described [27, 28]. All participants gave written informed consent, and 
the study was approved by the Institutional Review Board at each 
participating field center [27, 28].
Of the total HCHS/SOL study population, 14,440 individuals un-
derwent a sleep study at their baseline visit with sufficient somno-
graphy data for analyses [29]. For this case-control study [30], we 
identified 602 individuals who met the severe sleep disordered 
breathing case definition and who had plasma available for additional 
measurements. We then selected 602 controls, frequency-matched for 
sex and CKD stage, who did not have severe sleep disordered breathing. 
Our total population included 1204 individuals in whom we measured 
baseline plasma cFGF23, iFGF23 and phosphate (Fig. 1).
2.2. Primary exposure
The primary exposure was the presence of severe sleep disordered 
breathing. Participants were instructed on use of a Type 3 sleep apnea
and without CKD. In analyses restricted to those with or without CKD,
we compared those with severe sleep disordered breathing to controls
using standard descriptive statistics. We used linear regression to in-
vestigate the associations of severe sleep disordered breathing and
cFGF23 and iFGF23 expressed as a continuous variable. We used a si-
milar hierarchical modeling approach to that used in our total popu-
lation.
In sensitivity analyses, we replaced body mass index with waist
circumference, which may be a more accurate measure of adiposity, in
our multinomial and linear regression models.
Analyses were performed using SAS version 9.4 (Cary, NC, USA).
Two-sided p values < 0.05 were considered statistically significant.
3. Results
3.1. Associations of sleep disordered breathing with FGF23 levels
Table 1 presents clinical and demographic characteristics of the
1204 HCHS/SOL participants according to presence of severe sleep
disordered breathing. The median AHI in individuals with severe sleep
disordered breathing was 45.8 (IQR 35.5–62.5) compared to 2.6 (IQR
0.6–8.2) in the control group. Compared to controls, individuals with
severe sleep disordered breathing were older and had higher prevalence
of diabetes. Individuals with severe sleep disordered breathing also had
higher levels of inflammation and were more obese compared to con-
trols (CRP 3.4 mg/L, IQR 1.8–6.9 vs. 2.0 mg/L, IQR 0.9–4.8, p
value < 0.001; body mass index 35.2 ± 6.6 kg/m2 vs. 29.9 ± 5.8 kg/
m2, p value < 0.001, Table 1). Levels of cFGF23 were slightly higher in
individuals with severe sleep disordered breathing compared to con-
trols (66.2 RU/mL, IQR 52.8–98.4 vs. 61.2 RU/mL, IQR 49.5–80.1, p
value < 0.001, Table 1). iFGF23 levels did not differ between in-
dividuals with severe sleep disordered breathing and those without
(Table 1).
We investigated the associations of sleep disordered breathing with
ascending FGF23 quartiles using multinomial logistic regression ana-
lyses. In unadjusted analyses, individuals with severe sleep disordered
breathing had higher odds of belonging to cFGF23 Quartile 4 versus
Quartile 1 (cFGF23 Quartile 4 vs. Quartile 1 Odds Ratio [OR] 2.02, CI
1.46–2.80 Table 2). After adjustment for demographics, CKD-associated
risk factors, comorbidities, and CRP, individuals with severe sleep dis-
ordered breathing continued to have higher odds of belonging to
cFGF23 Quartile 4 versus Quartile 1 (cFGF23 Quartile 4 vs. Quartile 1
OR 1.93, CI 1.31–2.86 Table 2). After adjustment for body mass index,
the association was attenuated but remained significant (cFGF23
Quartile 4 vs. Quartile 1 OR 1.70, CI 1.12–2.59, Table 2). We did not
appreciate a significant relationship between severe sleep disordered
Fig. 1. Case control study design
Controls are frequency matched for sex and CKD stage.
Abbreviations: HCHS/SOL, Hispanic Community Health Study/Study of Latinos; N, number; SDB, sleep disordered breathing; CKD, chronic kidney disease.
Table 1
Characteristics of total population according to sleep disordered breathing
status.





Age, years 52.8 ± 11.2 48.7 ± 14.5 <0.001
Female, % 211 (35.1) 210 (34.9) 1.0
BMI, kg/m2 35.2 ± 6.6 29.9 ± 5.8 <0.001
SBP, mmHg 129.5 ± 18.5 125.8 ± 18.0 <0.001
Hypertension, N (%) 300 (49.8) 219 (36.4) <0.001
Diabetes, N (%) 232 (38.5) 139 (23.1) <0.001
CHD, N (%) 44 (7.3) 30 (5.0) 0.09
eGFR, mL/min/1.73m2 93.7 ± 22.8 97.2 ± 25.2 0.01
Albuminuria, N (%) 126 (20.9) 77 (12.8) <0.001
Albumin/creatinine ratio, mg/g 8.6 (5.2–21.6) 6.7 (4.4–13.1) <0.001
Phosphate, mg/dL 3.3 ± 0.5 3.3 ± 0.5 0.4
CRP, (mg/L) 3.4 (1.8–6.9) 2.0 (0.9–4.8) <0.001
C-terminal FGF23, RU/mL 66.2 (52.8–98.4) 61.2 (49.5–80.1) <0.001
intact FGF23, pg/mL 53.2 (42.8–67.7) 53.2 (42.8–71.2) 0.8
Apnea/hypopnea index 45.8 (35.5–62.5) 2.6 (0.6–8.2) <0.001
Results are reported as means ± standard deviation, proportions or medians
with interquartile ranges.
Abbreviations: N, number; SDB, sleep disordered breathing; BMI, body mass
index; SBP, systolic blood pressure; CHD, cardiovascular heart disease; eGFR,
estimated glomerular filtration rate; CRP, C-reactive protein FGF23, fibroblast
growth factor 23.
breathing and iFGF23 Quartiles (iFGF23 Quartile 4 vs. Quartile 1 OR
0.76, CI 0.52–1.11).
In the unadjusted linear regression analyses, severe sleep disordered
breathing was associated with higher cFGF23 levels expressed as a
continuous variable (β-estimate 0.12, CI 0.04–0.19, p value 0.002,
Table 3). The relationship remained significant after adjustment for
demographics, CKD risk factors, comorbidities, and CRP (β estimate
0.08, CI 0.02–0.15, p value 0.02). However, the association became
non-significant after the addition of body mass index (β estimate 0.07,
CI −0.005–0.14, p value 0.07, Table 3). We did not identify a sig-
nificant relationship between severe sleep disordered breathing and
iFGF23 levels (Table 3).
3.2. Subgroup analyses by CKD status
Of the 1204 individuals in the total population, 106 met criteria for
CKD. Clinical characteristics of individuals by severe sleep disordered
breathing status in individuals with and without CKD are presented in
Supplemental Tables 1 and 2. The mean eGFR in those with CKD and
4. Discussion
In a sample drawn from a large cohort of Hispanic/Latino patients
with and without CKD, we demonstrated that individuals with severe
sleep disordered breathing had slightly higher levels of cFGF23 than
those without severe sleep disordered breathing, but no difference in
iFGF23 levels. Body mass index or waist circumference were the main
confounders that attenuated the sleep disordered breathing-cFGF23
relationship in both linear and multinomial logistic regression analyses.
We did not appreciate any relationship with severe sleep disordered
breathing presence and iFGF23 in the total population or in the sub-
group with CKD. These results are broadly consistent with our hy-
potheses and suggest that in addition to iron deficiency and in-
flammation, sleep disordered breathing may be another clinical entity
in which we see upregulation of FGF23 transcription in osteocytes and
an elevation in cFGF23 but not iFGF23 levels.









































Model 1 adjust for age and gender.
Model 2 adjusts for covariates in Model 1 plus plasma phosphate, eGFR and
UACR.
Model 3 adjusts for covariates in Model 2 plus hypertension, diabetes presence,
cardiovascular disease, cigarette use.
Model 4 adjusts for covariates in Model 3 plus C-reactive protein.
Model 5 adjusts for covariates in Model 4 plus body mass index.
Abbreviations: FGF23, fibroblast growth factor 23; N, number; eGFR, estimated
glomerular filtration rate; UACR, urinary albumin-to-creatinine ratio.
Table 3
Adjusted associations of severe sleep disordered breathing with cFGF23 and iFGF23 levels expressed as continuous variables.
c-terminal FGF23 iFGF23
AHI≥ 30 vs. AHI < 30 Total N Parameter Estimate 95% CI p-Value Parameter estimate 95% CI p-Value
Unadjusted 1204 0.12 0.04–0.19 0.002 −0.02 −0.08–0.03 0.4
Model 1 1204 0.10 0.03–0.17 0.006 −0.03 −0.09–0.02 0.3
Model 2 1203 0.09 0.03–0.16 0.006 −0.03 −0.09–0.02 0.2
Model 3 1200 0.08 0.02–0.15 0.01 −0.03 −0.08–0.02 0.2
Model 4 1200 0.08 0.02–0.15 0.02 −0.03 −0.08–0.03 0.4
Model 5 1197 0.07 −0.005–0.14 0.07 −0.03 −0.09–0.03 0.3
Model 1 adjust for age and gender.
Model 2 adjusts for covariates in Model 1 plus plasma phosphate, eGFR and UACR.
Model 3 adjusts for covariates in Model 2 plus hypertension, diabetes presence, cardiovascular disease, cigarette use.
Model 4 adjusts for covariates in Model 3 plus C-reactive protein.
Model 5 adjusts for covariates in Model 4 plus body mass index.
Abbreviations: FGF23, fibroblast growth factor 23; N, number; CI, confidence interval; eGFR, estimated glomerular filtration rate; UACR, urinary albumin-to-
creatinine ratio.
Table 2
Adjusted associations of severe sleep disordered breathing presence with 
cFGF23 expressed as quartiles.
severe sleep disordered breathing was 46.3 ± 13.3 mL/min/1.73 m2 
and in those with CKD without severe sleep disordered breathing was 
45.0 ± 13.5 mL/min/1.73 m2 (Supplemental Table 1). Individuals 
with CKD and severe sleep disordered breathing had significantly 
higher body mass index and CRP than those with CKD but without 
severe sleep disordered breathing (body mass index 35.4 ± 6.7 kg/m2 
vs. 30.0 ± 6.8 kg/m2, p value < 0.001; CRP 6.1 mg/L IQR 2.7–11.6 vs. 
3.0 mg/L IQR 1.4–5.8, p value 0.001, Supplemental Table 1). cFGF23 
and iFGF23 levels were also higher in those with severe sleep dis-
ordered breathing than in those without severe sleep disordered 
breathing, however this did not reach significance (Supplemental 
Table 1). In multivariable analyses that were restricted to individuals 
with CKD, severe sleep disordered breathing was not associated with 
higher cFGF23 levels or iFGF23 levels (Supplemental Table 3).
3.3. Sensitivity analyses
Because waist circumference may be a more accurate measurement 
of adiposity compared to BMI, we replaced body mass index with waist 
circumference in our multinomial regression and linear regression 
models,. Our results were qualitatively similar. In our adjusted multi-
nomial regression analyses, the association between severe sleep dis-
ordered breathing and cFGF23 quartiles remained significant but was 
attenuated after adjustment for waist circumference (cFGF23 Quartile 4 
vs. Quartile 1 OR 1.62, CI 1.07–2.46). In our linear regression analyses 
investigating the associations between severe sleep disordered 
breathing and higher cFGF23 levels, similar to our models with body 
mass index, the association became non-significant after the addition of 
waist circumference (β estimate 0.06, CI −0.01–0.13, p value 0.11).
hypoxemia associates with different biological responses [53], and the
relationship of each of these to FGF23 homeostasis is unknown. We
demonstrate small and likely not clinically meaningful elevations in
cFGF23 levels in individuals with intermittent hypoxia. Whether
chronic hypoxia models would demonstrate larger differences in
cFGF23 levels is unknown. Human models of chronic hypoxia however,
also have limitations. For example, clinical scenarios of severe lung
disease are characterized as high inflammatory states, and a major
etiology of lung disease includes smoking, another known risk factor
associated with elevated FGF23 levels [54]. Due to the small sample
size of the CKD subgroup, we could not elucidate the impact of severe
sleep disordered breathing on FGF23 transcription or cleavage in CKD.
Although we were able to adjust for important confounders such as
body mass index and CRP in our cross-sectional analyses, we were
unable to adjust for iron indices and do not have longitudinal FGF23
measurements available. Finally, our study only included Hispanic/
Latino populations. Given that prior studies have demonstrated racial
variation in FGF23 levels [55], the generalizability of our findings may
be limited.
In settings of increased FGF23 transcription but normal FGF23
cleavage, which result in isolated cFGF23 elevation, we do not yet
understand what role c-terminal FGF23 fragments have given that the
biologic activity and maladaptive cardiovascular effects of FGF23 are
believed to be mediated by elevation in iFGF23 levels. However, ele-
vated levels of cFGF23 and iFGF23 both demonstrate associations with
morbidity and mortality in the general population and in those with
CKD [7, 9, 10]. It is critical to continue investigations that help eluci-
date factors that regulate FGF23 production and cleavage. The current
findings demonstrate that, similar to iron deficiency and inflammation,
severe sleep disordered breathing may be another clinical state char-
acterized by cFGF23 elevation in the absence of iFGF23 elevation.
Further human studies in alternative models of hypoxemia and in larger
CKD populations are needed to confirm our findings and ascertain the
impact of CKD on cFGF23 and iFGF23 levels in sleep disordered
breathing.
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FGF23 transcription [16]. When UMR-106 cells are grown in an oxygen 
deprived environment, expression of FGF23 mRNA increases. This 
parallels increases in HIF-1α protein expression, making it plausible 
that the appreciable increase in FGF23 mRNA expression is in response 
to cell hypoxia [16]. In vivo models support these findings. When an-
imals are exposed to a hypobaric atmosphere, cFGF23 increases by six 
fold, but iFGF23 remains unchanged [16]. This indicates that hypoxic 
environments may upregulate FGF23 transcription, which is re-
presented by an increase in cFGF23, along with a commensurate in-
crease in FGF23 cleavage resulting in normal bioactive iFGF23 levels 
[35]. Observational human studies also support a hypoxia-FGF23 re-
lationship. A single center study of 32 pediatric patients demonstrated 
that preoperative oxygen saturation level negatively correlated with 
cFGF23 levels, suggesting that hypoxemia may also regulate FGF23 
transcription in humans [36]. We now demonstrate that individuals 
with severe sleep disordered breathing are more likely to have elevated 
cFGF23 levels, but not iFGF23 levels.
Severe sleep disordered breathing is characterized by multiple 
overnight respiratory events associated with oxygen desaturation [37]. 
Prior reports of experiments conducted in cell cultures and animal 
models demonstrate that episodic hypoxia can directly impact the bone 
by increasing expression of HIF-1α and stimulating FGF23 transcription 
[38, 39]. Based on these data, we propose that intermittent nocturnal 
hypoxemia in sleep disordered breathing may directly trigger FGF23 
transcription in the bone resulting in elevated cFGF23 levels. We fur-
ther speculate that increases in FGF23 transcription induced by noc-
turnal hypoxemia in the absence of CKD is coupled to parallel increases 
in FGF23 cleavage, resulting in normal iFGF23 levels.
There are additional possible explanations for our findings. The 
elevation of cFGF23 in the severe sleep disordered breathing group may 
be a result of coexisting risk factors, such as elevated body mass index, 
inflammation, and hematologic indices in individuals with severe sleep 
disordered breathing. Prior investigations led by our group and others 
demonstrated significant associations between elevated body mass 
index and elevated FGF23 levels [40–45]. Indeed, adjustment for body 
mass index or waist circumference attenuated our results in both our 
multinomial logistic regression and linear regression analyses, and 
these covariates were the major confounders that rendered the re-
lationship in the linear regression models non-significant. The me-
chanisms underlying the associations of elevated body mass index and 
FGF23 levels remain unknown, but an overlap between metabolic and 
inflammatory signals is known to exist, which may contribute to an 
inflammatory milieu in obesity [46]. Both acute and chronic in-
flammation are known stimuli of FGF23 transcription [47]. In all 
comparisons, including our subgroups of CKD and non-CKD, those with 
severe sleep disordered breathing had significantly higher CRP values 
than those without severe sleep disordered breathing. Although we 
adjusted for CRP in our models, inflammation remains a biologically 
plausible mechanism that may link sleep disordered breathing and 
elevated body mass index with FGF23 elevation.
Prior investigations also demonstrate that erythropoietin levels may 
be elevated in individuals with sleep disordered breathing [48] and 
data suggest that erythropoietin may directly regulate FGF23 produc-
tion [16]. In addition, iron deficiency upregulates FGF23 transcription 
and may also be related to sleep related diseases [47, 49]. Although 
iron stores and erythropoietin are not available for our analyses, dis-
turbances in hematologic parameters represent another mechanism by 
which cFGF23 levels may be elevated in severe sleep disordered 
breathing. Finally, prior investigations in humans demonstrated a re-
lationship between obstructive sleep apnea and aberrant mineral me-
tabolism [50–52]. By triggering alterations in the mineral metabolism 
axis, intermittent hypoxia may indirectly lead to FGF23 elevation 
through alterations in vitamin D and parathyroid hormone.
We acknowledge additional limitations in our study. Sleep dis-
ordered breathing exemplifies a good model of intermittent hypoxemia, 
but differs from models of chronic hypoxemia. Each model of
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